Literature DB >> 30843167

BI 853520, a FAK-Simile of Prior FAK Inhibitors?

Rachael Chang Lee1, Hui K Gan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30843167     DOI： 10.1007/s11523-019-00621-z

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  11 in total

1.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

Review 2.  Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.

Authors:  Ekambaram Shanthi; Mudeenahally H Krishna; Gubbi M Arunesh; K Venkateswara Reddy; Jegatheesan Sooriya Kumar; Vellarkad N Viswanadhan
Journal:  Expert Opin Ther Pat       Date:  2014-08-12       Impact factor: 6.674

3.  Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

Authors:  Jeffrey R Infante; D Ross Camidge; Linda R Mileshkin; Eric X Chen; Rodney J Hicks; Danny Rischin; Howard Fingert; Kristen J Pierce; Huiping Xu; W Gregory Roberts; S Martin Shreeve; Howard A Burris; Lillian L Siu
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 4.  FAK inhibitors in Cancer, a patent review.

Authors:  Peng-Cheng Lv; Ai-Qin Jiang; Wei-Ming Zhang; Hai-Liang Zhu
Journal:  Expert Opin Ther Pat       Date:  2017-12-13       Impact factor: 6.674

Review 5.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

6.  A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Authors:  Suzanne F Jones; Lillian L Siu; Johanna C Bendell; James M Cleary; Albiruni R A Razak; Jeffrey R Infante; Shuchi S Pandya; Philippe L Bedard; Kristen J Pierce; Brett Houk; W Gregory Roberts; S Martin Shreeve; Geoffrey I Shapiro
Journal:  Invest New Drugs       Date:  2015-09-04       Impact factor: 3.850

7.  Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Authors:  Grant A Howe; Bin Xiao; Huijun Zhao; Khalid N Al-Zahrani; Mohamed S Hasim; James Villeneuve; Harmanjatinder S Sekhon; Glenwood D Goss; Luc A Sabourin; Jim Dimitroulakos; Christina L Addison
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

8.  Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.

Authors:  Ulrich A Hirt; Irene C Waizenegger; Norbert Schweifer; Christian Haslinger; Daniel Gerlach; Jürgen Braunger; Ulrike Weyer-Czernilofsky; Heinz Stadtmüller; Ioannis Sapountzis; Gerd Bader; Andreas Zoephel; Bojan Bister; Anke Baum; Jens Quant; Norbert Kraut; Pilar Garin-Chesa; Günther R Adolf
Journal:  Oncogenesis       Date:  2018-02-23       Impact factor: 7.485

9.  Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Authors:  Remy B Verheijen; Diane A J van der Biessen; Sebastien J Hotte; Lillian L Siu; Anna Spreafico; Maja J A de Jonge; Linda C Pronk; Filip Y F L De Vos; David Schnell; Hal W Hirte; Neeltje Steeghs; Martijn P Lolkema
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

10.  Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

Authors:  Maja J A de Jonge; Neeltje Steeghs; Martijn P Lolkema; Sebastien J Hotte; Hal W Hirte; Diane A J van der Biessen; Albiruni R Abdul Razak; Filip Y F L De Vos; Remy B Verheijen; David Schnell; Linda C Pronk; Monique Jansen; Lillian L Siu
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493
View more
  1 in total

1.  Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.

Authors:  Jinzhao He; Shun Zhang; Zhiwei Qiu; Xiaowei Li; Huihui Huang; William Jin; Yue Xu; Guangying Shao; Liang Wang; Jia Meng; Shuyuan Wang; Xiaoqiang Geng; Yingli Jia; Min Li; Baoxue Yang; Hua A Jenny Lu; Hong Zhou
Journal:  J Am Soc Nephrol       Date:  2021-09       Impact factor: 14.978
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.